Evidence map›Paper›PMID 41731635›Full record

ArticleJournal of medical case reports2026

Biallelic pathogenic hydroxymethylbilane synthase gene variants of a neurodegenerative disorder with progressive cystic leukoencephalopathy: a case report.

Gabriel Schacht, Miriam Elbracht, Anna-Elisabeth Minder, Thomas Stauch, Arzu Stoppe, Eva Lausberg, Martin Häusler

Abstract readCase Reports
In one paragraph

Article in Journal of medical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Gabriel SchachtDepartment of Pediatrics, Division of Neuropediatrics and Social Pediatrics, University Hospital RWTH Aachen, Aachen, Germany. gabriel-schacht@web.de.ORCID http://orcid.org/0000-0001-6513-5174
Miriam ElbrachtInstitute for Human Genetics and Genomic Medicine, Medical Faculty, RWTH Aachen University, Aachen, Germany.
Anna-Elisabeth MinderDivision of Endocrinology, Diabetology, Porphyria, Stadtspital Zurich, Triemli, Zurich, Switzerland.
Thomas StauchMVZ Labor PD Dr. Volkmann GbR, Karlsruhe, Germany.
Arzu StoppeDepartment of Pediatrics, Division of Neuropediatrics and Social Pediatrics, University Hospital RWTH Aachen, Aachen, Germany.
Eva LausbergInstitute for Human Genetics and Genomic Medicine, Medical Faculty, RWTH Aachen University, Aachen, Germany.
Martin HäuslerDepartment of Pediatrics, Division of Neuropediatrics and Social Pediatrics, University Hospital RWTH Aachen, Aachen, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHeterozygous mutations of the hydroxymethylbilane synthase gene can lead to acute intermittent porphyria, with episodic abdominal pain and neuropsychiatric symptoms. The heme precursors 5-aminolevulinic acid and porphobilinogen accumulate due to enzyme deficiency. Case reports of biallelic pathogenic hydroxymethylbilane synthase gene variants are very rare.

methodsThis case report presents a severely affected boy with biallelic pathogenic hydroxymethylbilane synthase gene variants and includes literature overview of other case reports and experimental data. CASE PRESENTATION: At the age of 2 years, a Caucasian boy with pathologic psychomotor development was diagnosed with biallelic pathogenic hydroxymethylbilane synthase gene variants. As in previous case reports, he did not exhibit symptoms of acute intermittent porphyria, but progressive cystic leukoencephalopathy and neurological decay. In his urine, 5-aminolevulinic acid and porphobilinogen were markedly elevated, but in cerebrospinal fluid just porphobilinogen. LITERATURE REVIEW: Data of human and animal studies indicate that neurologic symptoms of acute intermittent porphyria are caused by 5-aminolevulinic acid, which episodically accumulates from hepatic origin. Here, as long-term treatment, the inhibition of hepatic heme synthesis with the small interfering RNA givosiran has proven to be effective. In case of biallelic pathogenic hydroxymethylbilane synthase gene variants, the heme precursors 5-aminolevulinic acid or porphobilinogen originating from the liver or central nervous system could be causative, and absolute heme deficiency in the central nervous system is another hypothesis. However, parenterally administered heme, which is effective in acute intermittent porphyria, does not reach the central nervous system. In one case of biallelic pathogenic hydroxymethylbilane synthase gene variants, a liver transplantation did not lead to long-term benefit.

conclusionFor differential diagnosis of cystic leukoencephalopathy, biallelic pathogenic hydroxymethylbilane synthase gene variants should be considered. Its pathogenesis probably differentiates from acute intermittent porphyria. To date, there is no promising therapeutic approach.

Indexed as

Hydroxymethylbilane SynthaseLeukoencephalopathiesNeurodegenerative DiseasesPorphyria, Acute IntermittentAminolevulinic AcidChild, PreschoolHumansMaleMutationPorphobilinogenAminolevulinic AcidHydroxymethylbilane SynthasePorphobilinogen5-aminolevulinic acidCase reportHydroxymethylbilane synthaseLeukoencephalopathyPorphyria

Identifiers

PMID41731635
PMCPMC12952037

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.